Патогенетические механизмы и современные подходы к терапии вульвовагинальной атрофии и диспареунии у женщин в пост­менопаузе

1. Erekson E.A., Li F.Y., Martin D.K., Fried T.R. Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders. Menopause. 2016; 23(4): 368-75. https://dx.doi.org/10.1097/GME.0000000000000549
2. Fernandez-Alonso A.M., Cuerva M.J., Chedraui P., Pérez-López F.R. Screening and management of female sexual dysfunction during the second half of life. In: Pérez-López F., eds. Postmenopausal diseases and disorders. Cham (ZG): Springer; 2019: 165-85. https://dx.doi.org/10.1007/978-3-030-13936-0_10
3. Ярмолинская М.И., Колошкина А.В. Алгоритм диагностики и лечения генитоуринарного менопаузального синдрома. Акушерство и гинекология. 2024; 9(Приложение): 22-36.
4. Palma F., Volpe A., Villa P., Cagnacci A. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016; 83: 40-4. https://dx.doi.org/10.1016/j.maturitas.2015.09.001
5. Benini V., Ruffolo A.F., Casiraghi A., Degliuomini R.S., Frigerio M., Braga A. et al. New innovations for the treatment of vulvovaginal atrophy: an up-to-date review. Medicina (Kaunas). 2022; 58(6): 770. https://dx.doi.org/10.3390/medicina58060770
6. Donders G.G.G., Donders F.H.W.V. New developments in the management of vulvovaginal atrophy: a comprehensive overview. Expert Opin. Pharmacother. 2023; 24(5): 599-616. https://dx.doi.org/10.1080/14656566.2023.2194017
7. Pérez-López F.R., Vieira-Baptista P., Phillips N., Cohen-Sacher B., Fialho S.C.A.V., Stockdale C.K. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy. Gynecol. Endocrinol. 2021; 37(8): 740-5. https://dx.doi.org/10.1080/09513590.2021.1931100
8. Юренева С.В., Ермакова Е.И., Глазунова А.В. Диагностика и терапия генитоуринарного менопаузального синдрома у пациенток в пери- и постменопаузе (краткие клинические рекомендации). Акушерство и гинекология. 2016; 5: 138-44.
9. Глазунова А.В., Юренева С.В., Ежова Л.С. Вульвовагинальная атрофия: симптомы, влияние на эмоциональное благополучие, качество жизни и сексуальную функцию. Акушерство и гинекология. 2015; 12: 97-102.
10. Nappi R.E., Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) – results from an international survey. Climacteric. 2012; 15(1): 36-44. https://dx.doi.org/10.3109/13697137.2011.647840
11. Del Forno S., Raspollini A., Doglioli M., Andreotti A, Spagnolo E, Lenzi J. et al. Painful sexual intercourse, quality of life and sexual function in patients with endometriosis: not just deep dyspareunia. Arch. Gynecol. Obstet. 2024; 310(4): 2091-100. https://dx.doi.org/10.1007/s00404-024-07643-7
12. Палиева Н.В., Петров Ю.А., Тарасова А.Ю., Чехова А.И. Психологические и клинические нюансы женщин с диспареунией. Главный врач Юга России. 2023; 4(90): 49-52.
13. Faubion S.S., Kingsberg S.A., Clark A.L., Kaunitz A.M., Spadt S.K., Larkin L.C. et al. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause. 2020; 27(9): 976-92. https://dx.doi.org/10.1097/GME.0000000000001609
14. Brotman R.M., Shardell M.D., Gajer P., Fadrosh D., Chang K., Silver M.I. et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018; 25(11): 1321-30. https://dx.doi.org/10.1097/GME.0000000000001236
15. Zerbinati N., Serati M., Origoni M., Candiani M., Iannitti T., Salvatore S. et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med. Sci. 2015; 30(1): 429-36. https://dx.doi.org/10.1007/s10103-014-1677-2
16. Weber M.A., Limpens J., Roovers J.P.W.R. Assessment of vaginal atrophy: a review. Int. Urogynecol. J. 2015; 26(1): 15-28. https://dx.doi.org/10.1007/s00192-014-2464-0
17. Santoro N., Worsley R., Miller K.K., Parish S.J., Davis S.R. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J. Sex. Med. 2016; 13(3): 305-16. https://dx.doi.org/10.1016/j.jsxm.2015.11.015
18. Huang A.J., Gregorich S.E., Kuppermann M., Nakagawa S., Van Den Eeden S.K., Brown J.S. et al. Day-to-Day Impact of Vaginal Aging Questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause. 2015; 22(2): 144-54. https://dx.doi.org/10.1097/GME.0000000000000281
19. Erekson E.A., Yip S.O., Wedderburn T.S., Martin D.K., Li F.Y., Choi J.N. et al. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013; 20(9): 973-9. https://dx.doi.org/10.1097/GME.0b013e318282600b
20. Eaton A.A., Baser R.E., Seidel B., Stabile C., Canty J.P., Goldfrank D.J. et al. Validation of clinical tools for vaginal and vulvar symptom assessment in cancer patients and survivors. J. Sex. Med. 2017; 14(1): 144-51. https://dx.doi.org/10.1016/j.jsxm.2016.11.317
21. Jarząbek-Bielecka G., Plagens-Rotman K., Mizgier M., Opydo-Szymaczek J., Jakubek E., Kędzia W. The importance of use of the FSFI questionnaire in gynecology and venerology: a pilot study. Postepy Dermatol. Alergol. 2021; 38(3): 480-5. https://dx.doi.org/10.5114/ada.2021.107934
22. Alvisi S., Gava G., Orsili I., Giacomelli G., Baldassarre M., Seracchioli R. et al. Vaginal health in menopausal women. Medicina (Kaunas). 2019; 55(10): 615. https://dx.doi.org/10.3390/medicina55100615
23. Labrie F. Androgens in postmenopausal women: their practically exclusive intracrine formation and inactivation in peripheral tissues. In: Plouffe L., Rizk B., eds. Androgens in gynecological practice. Cambridge (UK): Cambridge University Press, 2015: 64-73. https://dx.doi.org/10.1017/CBO9781139649520.008
24. Tang J., Chen L.R., Chen K.H. The utilization of dehydroepiandrosterone as a sexual hormone precursor in premenopausal and postmenopausal women: an overview. Pharmaceuticals (Basel). 2021; 15(1): 46. https://dx.doi.org/10.3390/ph15010046
25. Fernand L. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019; 26(2): 220-4. http://dx.doi.org/10.1097/GME.0000000000001177
26. Ogino Y., Miyagawa Sh., Iguchi T. Subchapter 94D – Dehydroepiandrosterone. In: Takei Y., Ando H., Tsutsui K., eds. Handbook of hormones. Comparative endocrinology for basic and clinical research. Cambridge (MA): Academic Press; 2016: 513-4. https://doi.org/10.1016/B978-0-12-801028-0.00223-3
27. Гончаров Н.П., Дедов И.И., Кация Г.В., Гависова А.А., Сухих Г.Т. Особенности метаболизма дегидроэпиандростерона и современные возможности его использования для коррекции нарушений репродуктивной функции. Акушерство и гинекология. 2017; 7: 18-26.
28. Mohamad N.V., Razali N.C., Shamsuddin N.M. Dehydroepiandrosterone and bone health: mechanisms and insights. Biomedicines. 2024; 12(12): 2780. https://dx.doi.org/10.3390/biomedicines12122780
29. Martel C., Labrie F., Archer D.F., Ke Y., Gonthier R., Simard J.N. et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. J. Steroid Biochem. Mol. Biol. 2016; 159: 142-53. https://dx.doi.org/10.1016/j.jsbmb.2016.03.016
30. Pessina M.A., Hoyt R.F. Jr, Goldstein I., Traish A.M. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology. 2006; 147(1): 61-9. https://dx.doi.org/10.1210/en.2005-0870
31. Labrie F., Martel C., Belanger A., Pelletier G. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. J. Steroid Biochem. Mol. Biol. 2017; 168: 9-18. https://dx.doi.org/10.1016/j.jsbmb.2016.12.007
32. Johnston S., Bouchard C., Fortier M., Wolfman W. Guideline No. 422b: Menopause and Genitourinary Health. J. Obstet. Gynaecol. Can. 2021; 43(11): 1301-7.e1. https://dx.doi.org/10.1016/j.jogc.2021.09.001
33. Barton D.L., Sloan J.A., Shuster L.T., Gill P., Griffin P., Flynn K. et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018; 26(2): 643-50. https://dx.doi.org/10.1007/s00520-017-3878-2
34. Bouchard C., Labrie F., Derogatis L., Girard G., Ayotte N., Gallagher J. et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm. Mol. Biol. Clin. Investig. 2016; 25(3): 181-90. https://dx.doi.org/10.1515/hmbci-2015-0044
35. Pelletier G., Ouellet J., Martel C., Labrie F. Androgenic action of dehydroepiandrosterone (DHEA) on nerve density in the ovariectomized rat vagina. J. Sex. Med. 2013; 10(8): 1908-14. https://dx.doi.org/10.1111/jsm.12219
36. Villareal D.T., Holloszy J.O. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004; 292(18): 2243-8. https://dx.doi.org/10.1001/jama.292.18.2243
37. Archer D.F., Labrie F., Bouchard C., Portman D.J., Koltun W., Cusan L. et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015; 22(9): 950-63. https://dx.doi.org/10.1097/GME.0000000000000428
38. Portman D.J., Labrie F., Archer D.F., Bouchard C., Cusan L., Girard G. et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015; 22(12): 1289-95. https://dx.doi.org/10.1097/GME.0000000000000470
39. Bouchard C., Labrie F., Archer D.F., Portman D.J., Koltun W., Elfassi É. et al. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric. 2015; 18(4): 590-607. https://dx.doi.org/10.3109/13697137.2014.992012
40. Prasha Z.M., Paraton H. The effectiveness of prasterone vs placebo therapy as the vulvovaginal atrophy treatment in menopausal women: meta-analysis study. Medical and Health Science Journal. 2020; 4(2): 103-8. https://dx.doi.org/10.33086/mhsj.v4i2.1656
41. Labrie F., Bélanger A., Pelletier G., Martel C., Archer D.F., Utian W.H. Science of intracrinology in postmenopausal women. Menopause. 2017; 24(6): 702-12. https://dx.doi.org/10.1097/GME.0000000000000808
42. Matarazzo M.G., Sarpietro G., Fiorito D., Di Pasqua S., Ingrassano S., Panella M.M. et al. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 263: 67-71. https://dx.doi.org/10.1016/j.ejogrb.2021.06.009
43. Rubin R., Sanaee M., Yee A., Moyneur E., Dea K., Dury A.Y. Prevalence of urinary tract infections in women with vulvovaginal atrophy and the impact of vaginal prasterone on the rate of urinary tract infections. Menopause. 2025; 32(3): 217-27. https://dx.doi.org/10.1097/GME.0000000000002485
44. Инструкция по применению лекарственного препарата для медицинского применения Интрароса®. ЛП-N=(004049)-(РГ-RU) от 19.12.2023. Доступно по: https://grls.pharm-portal.ru/grls/a3f8d1ea-b7ec-4307-be3e-e73d11b24a3b#summary

Поступила 02.10.2025

Принята в печать 24.11.2025